The FDA’s 2023 approvals reflect a broad range of advances, from new drugs to treat oncology and hematology indications to first-in-class treatments for rare diseases like hereditary angioedema and neurofibromatosis […]
Read MoreThe FDA’s 2023 approvals reflect a broad range of advances, from new drugs to treat oncology and hematology indications to first-in-class treatments for rare diseases like hereditary angioedema and neurofibromatosis […]
Read More